Your privacy is very important for us. When you visit our website, please agree to use all cookies. For more information about how we use cookies, please visit our Privacy Policy.

中

News Center

6756758(2)-91.jpg

LaNova Medicines Completes USD 42 Million Series C1 Financing to Accelerate Clinical Progress and Innovation Platform Development

Learn More

All

2024

2023

2022

2021

2020

LM-108 Submitted US FDA Clinical Trial Application

CCR8 antibody LM-108 submitted US FDA clinical study application in December 2021. This study is a multi-center clinical study designed to evaluate the safety and initial efficacy of LM-108.

2021-12-23

Learn More
LaNova Medicines Launches R&D Center after Relocation

2021-11-30

Learn More
LaNova Medicines and Junshi Biosciences Enter into Multiple Combo Clinical Collaborations

2021-10-23

Learn More
LaNova Medicines and CBMG Enter into A Strategic Partnership

2021-10-22

Learn More
LaNova Medicines' LM-302 receives NMPA IND Approval

2021-10-15

Learn More
LaNova Medicines Holds Townhall Meeting to Celebrate 2nd Company Anniversary

2021-10-02

Learn More

4